Literature DB >> 25289414

[Comparison of different radio-chemotherapy-based treatments of primary nonresectable glioblastomas].

Carsten Nieder.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25289414     DOI： 10.1007/s00066-014-0718-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  8 in total

1.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

Review 2.  Treatment of unresectable glioblastoma multiforme.

Authors:  Carsten Nieder; Anca L Grosu; Sabrina Astner; Michael Molls
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

3.  Up-front chemotherapy with fotemustine (F) / cisplatin (CDDP) / etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas.

Authors:  M Frenay; C Lebrun; M Lonjon; P Y Bondiau; M Chatel
Journal:  Eur J Cancer       Date:  2000-05       Impact factor: 9.162

4.  Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.

Authors:  M Barrié; C Couprie; H Dufour; D Figarella-Branger; X Muracciole; K Hoang-Xuan; D Braguer; P M Martin; J C Peragut; F Grisoli; O Chinot
Journal:  Ann Oncol       Date:  2005-04-27       Impact factor: 32.976

5.  Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy.

Authors:  Patrick Beauchesne; Valerie Bernier; Charlotte Carnin; Luc Taillandier; Mohamed Djabri; Laurent Martin; Xavier Michel; Jean-Philippe Maire; Toufic Khalil; Christine Kerr; Thierry Gorlia; Roger Stupp; Remy Pedeux
Journal:  Neuro Oncol       Date:  2010-02-11       Impact factor: 12.300

6.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

7.  Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.

Authors:  B Chauffert; L Feuvret; F Bonnetain; L Taillandier; D Frappaz; H Taillia; R Schott; J Honnorat; M Fabbro; I Tennevet; F Ghiringhelli; J S Guillamo; X Durando; D Castera; M Frenay; C Campello; C Dalban; J Skrzypski; O Chinot
Journal:  Ann Oncol       Date:  2014-04-09       Impact factor: 32.976

8.  Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.

Authors:  Emil Lou; Katherine B Peters; Ashley L Sumrall; Annick Desjardins; David A Reardon; Eric S Lipp; James E Herndon; April Coan; Leighann Bailey; Scott Turner; Henry S Friedman; James J Vredenburgh
Journal:  Cancer Med       Date:  2013-01-24       Impact factor: 4.452
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.